Betsy Palal, MD
Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1376729079
Payments from drug & device makers
Across 422 payments — averaging $16,027 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$6.8M
- Amgen$2K
- Novo Nordisk$2K
- Tandem Diabetes Care, Inc.$700
- Abbott$621
- Sanofi-aventis U.S. LLC$471
- plus $4K from 35 others
Across 19 payments — averaging $6538.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$124K
What the payments were for
- Speaking & faculty fees$1,50016%
- Food & beverage$7,86884%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 114 | $6,754,039 |
| Amgen(2 entities) | 36 | $2,182 |
| Novo Nordisk | 61 | $1,628 |
| Tandem Diabetes Care, Inc. | 2 | $700 |
| Abbott | 32 | $621 |
| Sanofi-aventis U.S. LLC | 19 | $471 |
| Lilly USA, LLC | 18 | $444 |
| AstraZeneca(2 entities) | 13 | $417 |
| Dexcom, Inc. | 15 | $379 |
| AbbVie | 13 | $354 |
| Boehringer Ingelheim | 19 | $273 |
| Mannkind Corporation | 7 | $213 |
| Insulet Corporation | 6 | $212 |
| BETA Bionics, Inc. | 8 | $197 |
| Amneal Pharmaceuticals LLC | 4 | $156 |
| Recordati_rare_diseases_inc. | 6 | $136 |
| Neurocrine Biosciences, Inc. | 1 | $135 |
| Lifescan, Inc. | 5 | $94 |
| Xeris Pharmaceuticals, Inc. | 4 | $82 |
| Merck | 6 | $73 |
| BD | 1 | $60 |
| IBSA Pharma Inc. | 3 | $58 |
| Antares Pharma, Inc. | 4 | $57 |
| Novartis | 2 | $45 |
| Radius Health, Inc. | 2 | $40 |
| Amphastar Pharmaceuticals, Inc. | 2 | $39 |
| Corcept Therapeutics | 2 | $37 |
| Nevro Corp. | 1 | $33 |
| Ascensia Diabetes Care US Inc. | 2 | $33 |
| Bayer | 2 | $32 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Boston Scientific | 2 | $28 |
| Chiesi USA, Inc. | 1 | $22 |
| Embecta Corp. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Companion Medical, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Intra-sana Laboratories | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,410
- t:slim X2 insulin pump$700
- iLet Bionic Pancreas$330
- Ozempic$221
- Synthroid$163
- CRENESSITY$135
- Omnipod$134
- DEXCOM G6 TRANSMITTER$125
- Wegovy$125
- FARXIGA$124
- MOUNJARO$120
- EVENITY$120
- TOUJEO$115
- UNITHROID$112
- Repatha$109
- AFREZZA$102
How this compares
$6,763,459 in reported general payments places this provider in the 95th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 558 | $786,916 |
| JardianceEmpagliflozin | 305 | $343,126 |
| TrulicityDulaglutide | 213 | $342,001 |
| MounjaroTirzepatide | 219 | $286,819 |
| ProliaDenosumab | 73 | $127,483 |
| SynjardyEmpagliflozin/Metformin Hcl | 92 | $87,020 |
| Tresiba Flextouch U-100Insulin Degludec | 118 | $86,769 |
| Tresiba Flextouch U-200Insulin Degludec | 77 | $79,795 |
| RybelsusSemaglutide | 63 | $77,040 |
| Humalog Kwikpen U-200Insulin Lispro | 41 | $68,316 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $62,604 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $52,797 |
| Novolog FlexpenInsulin Aspart | 115 | $47,460 |
| Humalog Kwikpen U-100Insulin Lispro | 133 | $43,014 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 211 | $35,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,628 | $876,909673 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev | $444 | $635,726445 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta | $273 | $455,732421 claims |
| AmgenProlia | $2,182 | $127,48373 claims |
| AstraZenecaFarxiga | $417 | $35,12939 claims |
| MerckJanuvia | $73 | $19,15924 claims |
| Johnson & JohnsonInvokana | $13 | $17,81417 claims |
| AbbVieSynthroid | $354 | $13,104163 claims |
| Sanofi-aventis U.S. LLCLantus | $471 | $8,40044 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $156 | $6,791760 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Las Vegas
- Samer NakhleLas Vegas$14.5M
- Chakravarthy KannanLas Vegas$144K
- Michael UzmannLas Vegas$77K
- Molouk RahnemaLas Vegas$73K
- Nicholas VernettiLas Vegas$62K
- Firhaad IsmailLas Vegas$47K
- Bijan AhrariLas Vegas$47K
- Freddie ToffelLas Vegas$33K
- Mary Ann MartinLas Vegas$16K
- Serena KlughLas Vegas$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.